Reference — Electrolytes
High Potassium Emergency Management
Severe hyperkalemia is a life-threatening emergency requiring rapid, staged intervention. Management follows a consistent sequence: stabilize the cardiac membrane, shift potassium intracellularly, then eliminate the excess potassium from the body.
Educational use only. Hyperkalemia treatment requires immediate provider notification and orders. All medications and interventions in this reference require provider authorization. Always follow institutional protocols for critical electrolyte management. This material supports nursing education and exam review. It is not medical advice and is not a substitute for clinical judgment, institutional policy, or medical direction. Always follow facility protocols and current provider orders.
Overview
Hyperkalemia (serum K⁺ > 5.0 mEq/L) impairs cardiac conduction and muscle function. Severe hyperkalemia (> 6.5 mEq/L or with ECG changes) is a medical emergency that can progress to ventricular fibrillation and cardiac arrest if untreated.
The three-phase management approach:
- Stabilize: Protect the heart from fatal arrhythmias (calcium gluconate) — immediate, fastest acting
- Shift: Move potassium from blood into cells temporarily (insulin/glucose, sodium bicarbonate, albuterol) — effect within 15–60 minutes
- Remove: Eliminate potassium from the body (Kayexalate, furosemide, dialysis) — the only permanent solution
ECG Changes — Progressive with Rising K⁺
| K⁺ Level | ECG Finding | Clinical Urgency |
|---|---|---|
| 5.5 – 6.5 mEq/L | Peaked (tall, narrow, symmetric) T waves — earliest ECG sign; most prominent in precordial leads | Urgent — notify provider; begin monitoring |
| 6.5 – 7.5 mEq/L | Prolonged PR interval, widening QRS complex, flattening of P waves | Critical — immediate treatment required |
| > 7.5 mEq/L | Absent P waves, markedly widened QRS, sine wave pattern (QRS merges with T wave) | Emergency — pre-arrest; immediate intervention |
| > 8.0 mEq/L | Ventricular fibrillation, pulseless ventricular tachycardia, asystole | Cardiac arrest |
ECG changes do not always correlate linearly with potassium level. Some patients develop arrhythmias at lower levels. Treat ECG changes as seriously as the potassium number itself.
Phase 1 — Cardiac Stabilization
Calcium Gluconate (or Calcium Chloride)
Onset: 1–3 minutes • Duration: 30–60 minutes
- Mechanism: Calcium directly antagonizes the cardiac membrane effects of hyperkalemia — stabilizes the resting membrane potential and raises the threshold for depolarization (making the cell harder to depolarize). Does NOT lower the serum potassium level.
- Indication: ECG changes (peaked T waves, widened QRS) or K⁺ > 6.5 mEq/L
- Route: IV push, administered slowly over 2–3 minutes per order; calcium chloride is more potent (3× the elemental calcium) but more caustic — central line preferred for calcium chloride
- Caution: Do not administer calcium in the same IV line as sodium bicarbonate — precipitate will form. Flush line between medications.
- Effect is temporary (30–60 minutes) — concurrent shift and removal strategies must be initiated immediately
Phase 2 — Intracellular Potassium Shift
Shift strategies move potassium from the blood into cells — they lower serum K⁺ temporarily but do not eliminate potassium from the body. Removal strategies must follow.
Regular Insulin + Dextrose (D50W)
Onset: 15–30 minutes • Duration: 4–6 hours
- Insulin activates the Na⁺-K⁺-ATPase pump, driving K⁺ into cells
- Dextrose is given concurrently to prevent hypoglycemia — the most common adverse effect
- Monitor blood glucose every 30–60 minutes after administration; treat hypoglycemia promptly
- Typical order: 10 units regular insulin IV + 25–50 g D50W IV
Sodium Bicarbonate
Onset: 15–30 minutes
- Raises pH, which drives K⁺ into cells via H⁺-K⁺ exchange
- Most effective when concurrent metabolic acidosis is present (common in renal failure)
- Less effective in non-acidotic states — not first-line shift strategy alone
- Do not administer in the same line as calcium — precipitate will form
Inhaled Albuterol (Nebulized)
Onset: 15–30 minutes • Duration: 2–4 hours
- Beta-2 agonist activity stimulates Na⁺-K⁺-ATPase, driving K⁺ into cells
- Adjunctive agent — typically used in addition to insulin/dextrose
- Monitor heart rate — tachycardia is a common side effect; use with caution in cardiac patients
Phase 3 — Potassium Removal
Only removal strategies permanently reduce total body potassium. Shift strategies must be followed by removal to prevent rebound hyperkalemia.
Loop Diuretics (e.g., Furosemide)
- Promotes urinary potassium excretion
- Requires adequate renal function — ineffective in anuric or severely oliguric patients
- Onset of diuresis: 30–60 minutes IV
Sodium Polystyrene Sulfonate (Kayexalate)
- Cation exchange resin — binds potassium in the GI tract and removes it via the stool
- Oral or rectal administration; oral onset: hours; total effect over 24 hours
- Avoid in post-operative bowel or ileus patients — risk of intestinal necrosis
- Monitor for sodium retention — contains sodium which may be an issue in heart failure
Patiromer (Veltassa) / Sodium Zirconium Cyclosilicate (Lokelma)
- Newer potassium binders with improved safety profiles vs Kayexalate
- Patiromer: onset within hours; used primarily for chronic hyperkalemia management
- Lokelma: onset within 1 hour; indicated for acute and chronic hyperkalemia
Hemodialysis
- Most rapid and definitive method of potassium removal
- Indicated for: severe hyperkalemia with ECG changes unresponsive to medical management, anuric renal failure, or life-threatening hyperkalemia
- Requires nephrology consultation and vascular access
Nursing Priorities
- Initiate continuous cardiac monitoring immediately upon recognizing hyperkalemia
- Notify provider — obtain orders for all phases of treatment (stabilize, shift, remove)
- Establish IV access — large-bore peripheral or central line for calcium administration
- Identify and address the underlying cause: hold potassium-containing fluids, discontinue potassium supplements, reassess medications (ACE inhibitors, ARBs, potassium-sparing diuretics)
- Monitor blood glucose after insulin administration — hypoglycemia is the most common complication
- Reassess K⁺ level after interventions — repeat labs as ordered to confirm response
- Do not administer calcium and bicarbonate in the same IV line simultaneously
Related Resources
Standards & sources
Fact-checked Jun 20, 2026This page is written to align with Infusion Nurses Society (INS) Standards of Practice · Institute for Safe Medication Practices (ISMP) · Standard laboratory reference ranges. It is an educational summary, not a citation of any single document — always verify specific doses, values, and protocols against current guidelines and your facility policy. How we source content →